IRVINE, Calif., Dec. 21, 2015 /PRNewswire-iReach/ -- Dr. Rajiv Datar, President and CEO of DNX Biopharmaceuticals is pleased to announce the appointment of Dr. Jeffrey Cleland to the Board of Directors of the Company.
Photo - http://photos.prnewswire.com/prnh/20151220/317435
Dr. Cleland has 25 years of industry experience in research and development, including more than a decade at Genentech, Inc. His experience in startups includes major roles in obtaining more than $450 million in capital at stages from Series A through D and exit via IPO including over $300 million in capital raised as CEO. As the founding CEO of Versartis (VSAR), he led one of top biotech IPOs of all time. He held executive management positions at BaroFold, Novacea and Targesome, and has managed directly all aspects of pharmaceutical development and late-stage research. While at Genentech, Dr. Cleland served in product development and manufacturing roles. He held important leadership roles in the successful approval of two drugs, Herceptin® and Nutropin Depot®, as well as in early work on Lucentis®, Avastin®, Omnitarg®, and Kadcyla®. He holds a BS in Chemical Engineering from the University of California, Davis and a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology. Dr. Cleland has authored more than 100 articles and 4 books, and holds several issued patents.
Dr. Cleland is currently Interim Chief Executive Officer of Graybug, Inc., a biotechnology company developing technologies to treat eye diseases.
Dr. Datar comments “Dr. Cleland further strengthens our Board of Directors and brings acute knowledge of product differentiation which is key in the development and production of biobetters and biosimilars. With Dr Cleland’s appointment we are adding depth to an already strong Board of experts coming from all areas of the Biopharmaceutical field.”
Dr. Cleland further comments: “I look forward to working Dr. Datar and the Board to build a successful business focused on the application of a novel technology to create products with the potential to bring a significant therapeutic benefit to patients. DNX’s ability to improve safety, efficacy, and convenience of existing biologics provides a strong platform for value creation.”
About DNX
DNX is a private biopharmaceutical company developing long-acting therapeutic proteins for the treatment of patients with life-long diseases. Headquartered in Irvine, CA, USA, DNX is pursuing the development of new therapeutic proteins utilizing 21st century, half-life extension-based drug delivery technologies.
Media Contact:Rajiv Datar, DNX Biopharmaceuticals, Inc., +1.949.224.3489, Rajiv.Datar@dnxbio.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE DNX Biopharmaceuticals, Inc.
